Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy
Theresa Barberi, Alan D. Friedman · 2026
Read Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy by Theresa Barberi, Alan D. Friedman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13633648.txt.
Description
Barberi and Friedman present a study from twenty twenty-six on engineering human immune cells that resist calming signals for cancer therapy. Mouse work showed edited myeloid cells inflame tumors and aid T cells. Two regulator genes were the key edits there. The team now build the human version from marrow stem cells. Gene editing knocks out those regulators in stem cells. Conditions to grow and mature the cells are worked out. The edited cells become macrophages and face a calming signal.
Cells missing one regulator keep strong inflammatory programs despite it. Double edits help too, while other combos do not. Secreted proteins confirm the gene readouts. Patient trials must still test real benefit, the authors note.
Catalog record
| CREATOR | Theresa Barberi, Alan D. Friedman |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 71 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |